NCT04278729View on ClinicalTrials.gov

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions
Nephrotic SyndromeMembranous Nephropathy
Interventions
DRUG

Apixaban 5 MG

1 - 5 mg tablet taken orally twice a day

Trial Locations (1)

27517

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

American College of Clinical Pharmacy

OTHER

lead

University of North Carolina, Chapel Hill

OTHER